Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia. With its proprietary drug candidates aimed at effectively regulating phosphorus levels crucial for renal health, Unicycive is strategically positioned to address significant unmet medical needs within nephrology. The company's strong commitment to research and development, combined with its collaborative partnerships, enhances its potential for innovation and growth. As Unicycive advances through clinical trials, it represents a compelling investment opportunity for institutional investors targeting transformative solutions in the healthcare sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$5.03
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 12, 2026 | $-0.34 | $-0.06 | Beat +82.4% | $-0.06 | $0 | $0 | — | 1D Pre-0.4% | On-Day+7.8% | 1D Post+0.2% |
Q ended Mar 31, 2026 Reported May 12, 2026 | $-0.47 | $-0.53 | Miss -12.8% | — | $0 | $0 | — | 1D Pre+0.1% | On-Day+2.8% | 1D Post+4.2% |
Q ended Dec 31, 2025 Reported Mar 30, 2026 | $-0.45 | $-0.82 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre-3.6% |
| On-Day-4.4% |
| 1D Post+7.7% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.06 | $-0.33 | Miss -450.0% | — | $0 | $0 | — | 1D Pre+1.7% | On-Day+7.3% | 1D Post+3.7% |